OSCR 📈 Oscar Health - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6877931096
OSCR: Health Insurance, Reinsurance, Technology Platform
Oscar Health Inc, listed on the New York Stock Exchange as OSCR, is a key player in the US health insurance market, offering a range of plans tailored for individuals and small groups. The company's product portfolio is complemented by +Oscar, a cutting-edge platform designed to facilitate the transition to value-based care for both healthcare providers and payors. This platform leverages technology to streamline processes, enhance care coordination, and ultimately improve patient outcomes. Additionally, Oscar Health provides reinsurance products, further expanding its footprint in the health insurance sector.
With its roots dating back to 2012, Oscar Health has undergone significant evolution, including a name change from Mulberry Health Inc. to its current moniker in January 2021. This transformation reflects the company's growth and its commitment to innovating within the health insurance landscape. Headquartered in New York, New York, Oscar Health operates with a strong online presence, accessible through its website at https://www.hioscar.com. The company's common stock is traded under the ISIN code US6877931096, categorized under the Life & Health Insurance sub-industry within the GICS classification system.
Oscar Health's business model is built around providing affordable, high-quality health insurance plans that cater to the diverse needs of its customers. By integrating technology and data analytics into its core operations, the company aims to reduce healthcare costs, enhance the patient experience, and foster a more efficient healthcare delivery system. The +Oscar platform is a testament to this approach, offering a suite of tools and services that support value-based care initiatives, including care management, network development, and population health analytics. As the healthcare industry continues to shift towards more personalized and cost-effective care models, Oscar Health is well-positioned to play a significant role in this transformation.
Additional Sources for OSCR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
OSCR Stock Overview
Market Cap in USD | 4,092m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 2021-03-03 |
OSCR Stock Ratings
Growth 5y | -41.4% |
Fundamental | 0.49% |
Dividend | - |
Rel. Strength Industry | 60.4 |
Analysts | 3.83/5 |
Fair Price Momentum | 12.56 USD |
Fair Price DCF | 83.03 USD |
OSCR Dividends
No Dividends PaidOSCR Growth Ratios
Growth Correlation 3m | -66.9% |
Growth Correlation 12m | 29% |
Growth Correlation 5y | -0.1% |
CAGR 5y | -21.42% |
CAGR/Mean DD 5y | -0.31 |
Sharpe Ratio 12m | 0.86 |
Alpha | 8.65 |
Beta | 1.69 |
Volatility | 73.39% |
Current Volume | 2032.3k |
Average Volume 20d | 4163.5k |
As of December 30, 2024, the stock is trading at USD 13.80 with a total of 2,032,318 shares traded.
Over the past week, the price has changed by +1.47%, over one month by -20.37%, over three months by -34.94% and over the past year by +50.82%.
Neither. Based on ValueRay Fundamental Analyses, Oscar Health is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OSCR as of December 2024 is 12.56. This means that OSCR is currently overvalued and has a potential downside of -8.99%.
Oscar Health has received a consensus analysts rating of 3.83. Therefor, it is recommend to buy OSCR.
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, OSCR Oscar Health will be worth about 14.2 in December 2025. The stock is currently trading at 13.80. This means that the stock has a potential upside of +2.9%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 19.4 | 40.3% |
Analysts Target Price | 8.7 | -37.2% |
ValueRay Target Price | 14.2 | 2.9% |